What happened this week? Woodford spent €800m, CRISPR discoverer moves to Berlin, the first Bacteria-made ink…

Encouraging facts for the European Biotech ecosystem this week! Neil Woodford’s mega Biotech fund is gathering new money to pour over the European companies. Definitely good news for the financing of companies in Europe, which still lags behind the US.

Another interesting fact is that one of the co-discoverer of CRISPRs, the biggest discovery of the century, chose to move to the German capital.

Top scientists + fresh money = definitely good news for European biotechs! 


Find out more in this week’s highlights:

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund


© Woodford Patient Capital Trust

Neil Woodford is a legendary British Biotech investor who opened a new mega €1.1Bn Biotech fund, named Woodford Patient Capital Trust, the biggest UK trust ever!


Emmanuelle Charpentier, co-discoverer of CRISPR-Cas9 Technology, comes to Berlin!

Emmanuelle Charpentier

© Helmholtz / Hallbauer&Fioretti

French, young and brilliant, Emmanuelle Charpentier will now be working as a director at the Max Planck Institute for Infection Biology in Berlin!


Pili Printed their First Page with Bacteria-Made Ink!


© Pili

Pili is a group of seven young dedicated entrepreneurs who dream of replacing the toxic pigments used in today’s ink with natural, non-toxic, recycable ink made by bacteria.


Oxitec’s revolutionary Genetically Modified Insects acquired by Intrexon for €146M


© Intrexon

US-based Intrexon absorbed the Oxford University’s spinout with its unique technology to accelerate the crackdown of dengue infections and crop damages.


FDA Approves Worlds’ First 3D-Printed Drug

Aprecia 3D printing

In a year that has seen everything from wedding cakes to violins receiving the three dimensional-printing treatment, it was only a matter of time before the pharmaceutical industry found a use for the trendy method of manufacture.


Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.